Dose escalation of ORIN1001 administered as a single agent in patients with advance solid tumors. ORIN1001 is administered daily as a tablet.~Dose escalation of ORIN1001 administered in combination with standard of care in patients with esophageal carcinoma, triple negative breast cancer, ER+/HER2- metastatic breast cancer, hepatocellular carcinoma, metastatic castration-sensitive prostate cancer, pancreastic cancer, ovarian cancer and non-small cell lung cancer.~Dose expansion of single agent or combination therapy with ORIN1001 in patients with advanced solid tumors.
Dose escalation of ORIN1001 in patients with advanced solid tumors.~Dose escalation of ORIN1001 in combination with standard of care in patients with esophageal carcinoma, metastatic breast cancer, hepatocellular carcinoma, metastatic prostate cancer, pancreatic cancer, ovarian cancer and non-small cell lung cancer.~Dose expansion of ORIN1001 as a single agent or in combination with standard of care in patients with advanced solid tumors.